2026 Annual Conference of the Chinese Antibody Society (ChAbS): Highlights and Event Recap

The 2026 ChAbS Annual Conference, “10 Years Together: Forging the Future of Antibody Therapeutics,” was held on May 9-10, 2026, in Cambridge, MA.

Key Trends

1. Antibody-drug conjugates are moving toward multi-payload and dual-conjugation designs to address resistance, tumor heterogeneity, linker stability, and therapeutic index.  

2. Bispecific and biparatopic next-generation antibody engineering, with emphasis on manufacturability, chain pairing, epitope geometry, and receptor signaling control.  

3. Antibody delivery for blood-brain barrier transport, organoid biology, synthetic neoantigens, and photomedicine.  

4. Immunotoxicity and translational safety as issues for immune-stimulating antibody conjugates and other immune-activating modalities.  

5. AI-enabled antibody design and large-scale manufacturing are now positioned as enabling infrastructure for antibody therapeutic discovery, optimization, and commercialization.  

1. Synthetic Neoantigens, Checkpoint Biology, and Immune-Directed Cancer Therapy

• A strategy for linking targeted therapy to immunotherapy by using covalent KRAS inhibitors to generate synthetic neoantigens was discussed. 

• New developments in CTLA-4, PD-1, PD-L1, and LAG3-directed antibody therapies after a decade of slower improvement in first-generation immuno-oncology agents.  

• Immune-stimulating antibody conjugates are designed to deliver immune agonists into the tumor microenvironment. The key translational issue is balancing local immune activation with systemic inflammatory toxicity, on-target/off-tumor activation, and immunogenicity.  

ADC High-throughput Antibody Conjugation →

2. ADC Innovation: Payload Architecture, Linker Chemistry, and Bispecific ADCs

• Flexible dual-payload ADCs are being designed using site-specific conjugation, stable connectors, and hydrophilic payload-linkers. Other important methods include rational linker design, site-specific homogeneous conjugation, branched linkers, and tunable protease-cleavable mechanisms. The scientific focus was improving plasma stability while enabling selective payload release in tumors. 

• ADC DAR combinations such as 6+2 and 4+4 and was presented as a strategy to improve efficacy and therapeutic index.  

• Bispecific ADC programs can address tumor heterogeneity and improve targeting precision.  

3. Bispecific, Biparatopic, and Single-Domain Antibody Engineering

• Epitope selection can govern whether biparatopic antibodies behave in trans-binding agonistic modes or cis-binding antagonistic mode. 

• Fully human single-domain antibodies as building blocks for IgG-format bispecific antibodies can reduce chain mispairing and heterogeneity while retaining natural antibody architecture and dual antigen binding.  

• Artificial intelligence may reshape antibody therapeutics by 2030, with participation from antibody design, pharmaceutical R&D, computational biology, and machine learning groups.  

4. Antibody Delivery, Photomedicine, and Tissue-Specific Targeting

• Photosensitizer-antibody conjugates and photo-caging strategies for spatial and temporal control could expand chemical diversity in antibody conjugates and reduce off-site toxicity through light- or radiation-controlled activation.  

• The blood-brain barrier can be crossed with antibody engineering for receptor-mediated transcytosis using transferrin receptor targeting. 

• Integrin agonists and antagonists may regulate organoid formation, with the goal of generating more tissue-like, vascularized, mixed-lineage organoids.

Thank you to everyone who visited our booth at the 2026 Annual Conference of the Chinese Antibody Society (ChAbS) to learn about our services! We had a fantastic time chatting with you and how it can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com or visit our website at www.biointron.com.